New Study On Adjunctive Use of E. coli Nissle Fails to Improve Ulcerative Colitis Outcomes

New Study On Adjunctive Use of E. coli Nissle Fails to Improve Ulcerative Colitis Outcomes
Ulcerative colitis is a form of inflammatory bowel disease (IBD), an inflammation of the colon characterized by ulcers, with a yearly incidence of 1 to 20 cases per 100,000 individuals, and a prevalence of 8 to 246 per 100,000 individuals. UC is an intermittent disease, with periods of exacerbated symptoms, such as constant diarrhea mixed with blood, and periods that are mostly symptom-free. Although the symptoms of ulcerative colitis can sometimes diminish spontaneously, the disease normally requires treatment in order to go into remission. Even though this disease has no known cause, researchers believe that there are probably genetic factors that contribute to its susceptibility in patients, along with some environmental factors as well. Furthermore, evidence exists for the pathogenic role of the enteric flora in ulcerative colitis. Since probiotics contain living microorganisms that exert health effects on the host, the probiotic bacterium Escherichia coli Nissle 1917 (EcN) has been used to maintain and induce clinical remission in UC. A team of researchers from Hvidovre University Hospital, Copenhagen, Denmark, designed a single-center double-blinded randomized placebo controlled clinical trial to study the effect of Ciprofloxacin and/or orally administered EcN as add-on to conventional therapies in patients with active UC. A total of 100 patients with a Colitis Activity Index (CAI) score of at least 6 were recruited and randomly assigned 500 mg ciprofloxacin twice daily (n=25) or placebo (n=25) for 1 week, followed by 100 mg E. coli Nissle (EcN; n=25) daily for 4 days followed by 100 mg twice daily for the remainder of the period or placebo (n=25) for 7 weeks. All four regimens were administered as adjunctive therapy. The research
Subscribe or to access all post and page content.